Clinical trials: Tick-Borne Disease
Encephalitis, Tick-Borne
TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209)
The purpose of this study is to assess the seropersistence of TBE antibodies in children and adolescents aged 1 to 15 years at the time of their first vaccination, 24 months and 34 months after completion of primary immunization…
- Trial name
- NCT00161967
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lyme Borreliosis, Nervous System
Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis
Observer-blind, partially randomized, multi-center dose escalation Phase I study in healthy adults below 40 years of age. 180 subjects will be enrolled in 6 treatment groups (different doses; different formulation: with/without…
- Trial name
- NCT03010228
- Testing
- VLA15 with Alum, VLA15 without Alum
- Where
- 5 sites in United States, Belgium
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lyme Disease
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
- Trial name
- NCT05975099
- Testing
- mRNA-1975, mRNA-1982
- Where
- 20 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Encephalitis, Tick-borne
Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children
The objective of this study is to assess the TBE antibody persistence approximately three years after administration of a TBE booster vaccination with FSME-IMMUN 0.25 ml Junior in children who received either 0.25 mL or 0.5 mL…
- Trial name
- NCT00163618
- Testing
- Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl
- Where
- 4 sites in Austria
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Lyme Disease
Novel Diagnostics for Early Lyme Disease
There are more than 300,000 new cases of Lyme disease every year in the US. Lyme disease is a dangerous bacterial infection transmitted by tick bites and it becomes increasingly severe as the infection progresses.
- Trial name
- NCT03963635
- Testing
- MicroB-plex Lyme Immunoassay
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- MicroB-plex, Inc.
Tick Borne Encephalitis, Virus Diseases
Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules
The aim of this study is to investigate the immunogenicity response in adults up to 10 years after one booster dose. Data collected from this study will allow for greater information to prescribers who administer TBE vaccine, so…
- Trial name
- NCT01562444
- Testing
- Blood draw
- Where
- Czechia
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Encephalitis, Tick-Borne
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
blood draw five years after booster-immunization with TBE vaccine to investigate immunogenicity in children
- Trial name
- NCT00452621
- Testing
- blood draw
- Where
- 8 sites in Germany
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- Novartis
Tick-borne Encephalitis (TBE)
TBE Seropersistence up to 10 Years After First Booster in Adults
The purpose of this study is to evaluate TBE antibody persistence from 7 to 10 years after the first booster TBE vaccination with FSME-IMMUN 0.5ml.
- Trial name
- NCT01582698
- Testing
- FSME-IMMUN 0.5 ml
- Where
- 2 sites in Poland
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lyme Disease
ImmuneSense Lyme Study
ImmuneSense Lyme is a study, which is designed to better understand the immune response to Lyme disease. This is critically important because the immune system may be able to tell us important information about how our own bodies…
- Trial name
- NCT04422314
- Testing
- T-Detect Lyme
- Where
- 34 sites in United States
- Volunteers
- 893 people
- Sponsor
- Adaptive Biotechnologies
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all volunteers who completed two vaccinations in one of the three…
- Trial name
- NCT00161889
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 19 sites in Germany
- Volunteers
- 615 people, healthy volunteers welcome
- Sponsor
- Pfizer
Lyme Disease
A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease
This study will evaluate Advanced Laboratory Services Borrelia diagnostic test by culturing Borrelia spirochetes from human serum in subjects with early or late Lyme disease. This is an 8 month study.
- Trial name
- ALSIBDT (NCT02741609)
- Testing
- Borrelia Diagnostic Test
- Where
- 16 sites in United States
- Volunteers
- 218 people
- Sponsor
- Advanced Laboratory Services, Inc.
Lyme Borreliosis
Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population
VLA15-221 is a Phase 2 study, which will be conducted in two parts: Main Study Phase (Part A) and Booster Phase (Part B). The study will compare the safety and immunogenicity of two different primary immunization schedules…
- Trial name
- NCT04801420
- Testing
- VLA15
- Where
- 19 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-Borne Encephalitis
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
- Trial name
- NCT04648241
- Testing
- TBE vaccine 0.5 mL, TBE vaccine 0.25 mL
- Where
- 6 sites in Japan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine will be investigated in healthy children aged 6 to 16 years.
- Trial name
- NCT00161798
- Testing
- Tick-borne encephalitis vaccine
- Where
- 23 sites in Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Lyme Borreliosis
Performance Evaluation of the DualDur In Vitro Diagnostic System in the Diagnosis of Lyme Borreliosis
The clinical data from the clinical trial will be used to assess the performance, sensitivity and specificity of the experimental DualDur In Vitro Diagnostic System.
- Trial name
- NCT03873974
- Testing
- DualDur dark-field microscopic test, DualDur dark-field automatic microscopic test, Western blot IgM and IgG
- Where
- 8 sites in Austria, Czechia and 4 more
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Lyme Diagnostics Ltd.
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years
The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all subjects who completed two vaccinations in one of the three…
- Trial name
- NCT00161850
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 25 sites in Austria, Germany
- Volunteers
- 615 people, healthy volunteers welcome
- Sponsor
- Pfizer
Bell's Palsy, Ramsay Hunt Syndrome
Safety and Effectiveness of the BlinkER System in Participants With Facial Nerve Palsy
Prospective, single-arm, multicenter, single-masked, pivotal study to Evaluate the Safety and Effectiveness of the Blinker system in Participants with Facial Nerve Palsy.
- Conditions
- Bell's Palsy, Ramsay Hunt Syndrome, Lyme Disease, Facial Palsy
- Trial name
- Paralysis (NCT06542289)
- Testing
- BlinkER device.
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Neurotrigger Ltd
Lyme Disease
Lyme Test Indication Combinations (LyTIC) Study
To establish performance of individual tests and combinations of tests (serological, molecular and cellular tests) in early Lyme infection diagnosis
- Trial name
- LyTIC (NCT03201042)
- Testing
- PCR based assay, Serology based assay, Tcell based assay
- Where
- 60 sites in United States
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Oxford Immunotec
Healthy Volunteer
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in the killing of ticks after they have attached to human…
- Trial name
- NCT05387083
- Testing
- Low Dose TP-05, High Dose TP-05
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Lyme Disease
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)
This clinical study will evaluate the safety, reactogenicity, and immunogenicity of monovalent mRNA-1982, a messenger ribonucleic acid (mRNA) vaccine to prevent Lyme disease in healthy adults aged 18 to 70 years old.
- Trial name
- NCT07561294
- Testing
- mRNA-1982
- Where
- 8 sites in Canada
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.